Regeneron Pharmaceuticals (REGN) Free Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $848.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 3.98% year-over-year to $848.3 million in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 32.6% increase from a year earlier, with the FY2025 full-year figure at $4.1 billion, up 11.35% from the prior year.
• Free Cash Flow eased to $848.3 million in Q1 2026 per REGN's latest filing, from $922.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $2.0 billion in Q1 2022 and bottomed at $336.3 million in Q2 2024.
• The 5-year median for Free Cash Flow is $922.0 million (2025), against an average of $993.7 million.
• Across the five-year window, Free Cash Flow slumped 85.17% in 2022 and soared 255.31% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $1.6 billion in 2022, then plunged by 46.53% to $838.3 million in 2023, then climbed by 26.83% to $1.1 billion in 2024, then fell by 13.28% to $922.0 million in 2025, then declined by 7.99% to $848.3 million in 2026.
• Per Business Quant, the three latest REGN Free Cash Flow figures stand at $848.3 million (Q1 2026), $922.0 million (Q4 2025), and $1.1 billion (Q3 2025).